Siddique Sunny, Wang Rong, Gaddy Jacquelyne J, Stempel Jessica M, Warren Joshua L, Gross Cary P, Ma Xiaomei
Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, USA.
Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, New Haven, USA.
J Gen Intern Med. 2025 Feb;40(3):611-619. doi: 10.1007/s11606-024-09153-3. Epub 2024 Nov 4.
Colorectal cancer (CRC) screening is underutilized among those with lower socioeconomic status and in racial and ethnic minoritized populations who have been disproportionately impacted by COVID.
To compare disparities in CRC screening before and after the onset of the COVID pandemic among privately insured individuals.
Retrospective cohort study using deidentified claims data from the USA between January 1, 2017, and December 31, 2022.
Blue Cross Blue Shield beneficiaries aged 50-75 years with average risk of CRC.
MAIN MEASURE(S): Mean screening use was compared by demographic and area-level socioeconomic factors between the periods preceding (January 1, 2017 to February 28, 2020) and following (July 1, 2020 to December 31, 2022) the onset of the COVID pandemic. Difference-in-differences analysis was used to evaluate changes in screening differences.
Our study included 21,724,223 beneficiaries. Compared to males, females had higher screening in both periods (p < 0.05), and this sex difference in screening increased 1.63% (95% confidence interval [CI]: 1.32%, 1.94%) following the onset of the pandemic. Compared to residents in areas with high socioeconomic status (SES), low SES area residents had lower screening (p < 0.001) during both periods. Furthermore, this difference grew 4.32% (95% CI, 3.76%, 4.88%) during the post-onset period. Metropolitan area residents had higher screening than non-metropolitan area residents during both periods (p < 0.001); however, this difference decreased 0.77% (95% CI, 0.34%, 1.20%) during the post-onset period. Among beneficiaries with high risk of CRC, the difference in screening based on social deprivation index and metropolitan area status increased 6.99% (95% CI, 5.77%, 8.20%) and 1.82% (95% CI, 0.88%, 2.74%), respectively.
Among privately insured individuals, CRC screening after the COVID pandemic recovered unevenly based on sex, area-level socioeconomic measures, and metropolitan area status, with pre-pandemic disparities persisting and even worsening for some of the factors.
在社会经济地位较低以及在新冠疫情中受影响尤为严重的少数种族和族裔人群中,结直肠癌(CRC)筛查的利用率较低。
比较新冠疫情爆发前后,私人保险人群中结直肠癌筛查的差异。
回顾性队列研究,使用2017年1月1日至2022年12月31日期间美国去识别化的理赔数据。
年龄在50 - 75岁、患结直肠癌平均风险的蓝十字蓝盾保险受益人。
比较新冠疫情爆发前(2017年1月1日至2020年2月28日)和爆发后(2020年7月1日至2022年12月31日)按人口统计学和地区层面社会经济因素划分的平均筛查使用率。采用差异中的差异分析来评估筛查差异的变化。
我们的研究纳入了21,724,223名受益人。与男性相比,女性在两个时期的筛查率都更高(p < 0.05),且疫情爆发后这种筛查的性别差异增加了1.63%(95%置信区间[CI]:1.32%,1.94%)。与社会经济地位高(SES)地区的居民相比,社会经济地位低的地区居民在两个时期的筛查率都较低(p < 0.001)。此外,在疫情爆发后的时期,这种差异增长了4.32%(95% CI,3.76%,4.88%)。在两个时期,大都市地区居民的筛查率都高于非大都市地区居民(p < 0.001);然而,在疫情爆发后的时期,这种差异下降了0.77%(95% CI,0.34%,1.20%)。在患结直肠癌高风险的受益人中,基于社会剥夺指数和大都市地区地位的筛查差异分别增加了6.99%(95% CI,5.77%,8.20%)和1.82%(95% CI,0.88%,2.74%)。
在私人保险人群中,新冠疫情后的结直肠癌筛查在性别、地区层面社会经济指标和大都市地区地位方面恢复不均衡,疫情前的差异仍然存在,甚至在某些因素上有所加剧。